NCT04509193 - A Study Using Electronic Health Information to Learn About Rivaroxaban Compared to Warfarin in Participants With Non-valvular Atrial Fibrillation (NVAF) and Diabetes | Biotech Hunter

Enrollment

116,049

Participants

Timeline

Start Date

August 21, 2020

Primary Completion Date

July 31, 2021

Study Completion Date

July 31, 2021

Conditions

Atrial Fibrillation

Interventions

DRUG

Rivaroxaban (Xarelto, BAY59-7939)

Participants receive rivaroxaban (per written prescription, medication administration or self-report of medication use)

DRUG

Warfarin

Participants receive warfarin (per written prescription, medication administration or self-report of medication use)

Trial Locations (1)

US Optum De-Identified EHR data, Whippany